Research ExplorerPublicationsGerman multicenter real-world registry of stenting for super...

German multicenter real-world registry of stenting for superficial femoral artery disease: clinical results and predictive factors for revascularization

Standard

German multicenter real-world registry of stenting for superficial femoral artery disease: clinical results and predictive factors for revascularization. / Krankenberg, Hans; Tübler, Thilo; Sixt, Sebastian; Fischer, Matthias; Schmiedel, Rainer; Schulte, Karl-Ludwig; Balzer, Jörn O; Kieback, Arne; Fiehn, Eduard; Wittenberg, Günther; Ali, Tammam; Tiefenbacher, Christiane; Jahnke, Thomas; Steinkamp, Hermann J; Wegscheider, Karl; Treszl, András; Ingwersen, Maja; Zeller, Thomas.

In: J ENDOVASC THER, Vol. 21, No. 4, 01.08.2014, p. 463-471.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Krankenberg, H, Tübler, T, Sixt, S, Fischer, M, Schmiedel, R, Schulte, K-L, Balzer, JO, Kieback, A, Fiehn, E, Wittenberg, G, Ali, T, Tiefenbacher, C, Jahnke, T, Steinkamp, HJ, Wegscheider, K, Treszl, A, Ingwersen, M & Zeller, T 2014, 'German multicenter real-world registry of stenting for superficial femoral artery disease: clinical results and predictive factors for revascularization', J ENDOVASC THER, vol. 21, no. 4, pp. 463-471. https://doi.org/10.1583/13-4625R.1

APA

Krankenberg, H., Tübler, T., Sixt, S., Fischer, M., Schmiedel, R., Schulte, K-L., Balzer, J. O., Kieback, A., Fiehn, E., Wittenberg, G., Ali, T., Tiefenbacher, C., Jahnke, T., Steinkamp, H. J., Wegscheider, K., Treszl, A., Ingwersen, M., & Zeller, T. (2014). German multicenter real-world registry of stenting for superficial femoral artery disease: clinical results and predictive factors for revascularization. J ENDOVASC THER, 21(4), 463-471. https://doi.org/10.1583/13-4625R.1

Vancouver

Krankenberg H, Tübler T, Sixt S, Fischer M, Schmiedel R, Schulte K-L et al. German multicenter real-world registry of stenting for superficial femoral artery disease: clinical results and predictive factors for revascularization. J ENDOVASC THER. 2014 Aug 1;21(4):463-471. https://doi.org/10.1583/13-4625R.1

Bibtex

@article{3625d7431f2b41198ee20720c745e726,
title = "German multicenter real-world registry of stenting for superficial femoral artery disease: clinical results and predictive factors for revascularization",
abstract = "PURPOSE: To investigate nitinol stent treatment of superficial femoral artery (SFA) lesions and the impact of different risk factors on the need for clinically driven target lesion revascularization (TLR) in a large, real-world population of claudicants.METHODS: Patients presenting with symptomatic SFA stenosis >70% were consecutively enrolled in the 13-center MARIS prospective registry (ClinicalTrials.gov identifier NCT01067885). There was no restriction on lesion length, thus leading to the inclusion of a real-world as well as high-risk patient cohort. The 998 participating patients (657 men; mean age 67.4±9.2 years) had 1050 lesions treated with the same nitinol stent type. The mean lesion length was 9.5±9.6 cm (range 0.5-44; median 8.0); more than a third of the lesions (450, 42.9%) were total occlusions. The primary endpoint was the need for clinically driven target lesion revascularization (TLR) at 12 months.RESULTS: Acute technical success was achieved in 1042 (99.2%) lesions. Restenosis occurred in 187 (23.7%) and reocclusion in 79 (10.0%) lesions at 12 months. The primary endpoint of TLR at 12 months was reached by 136 (17.2%) patients. The periprocedural complication rate was 5.4%. Independent predictors of TLR were female gender [odds ratio (OR) 0.5, 95% confidence interval (CI) 0.3 to 0.7, p<0.001] and lesion length >20 cm vs. 10 cm (OR 2.7, 95% CI 1.1 to 6.6, p=0.029) and 10-20 cm vs. 10 cm (OR 1.9, 95% CI 1.0 to 4.1, p=0.047).CONCLUSION: Stent implantation in the SFA is safe and associated with favorable acute and midterm results in a real-world setting. Lesion length and female gender were identified as independent risk factors for TLR.",
author = "Hans Krankenberg and Thilo T{\"u}bler and Sebastian Sixt and Matthias Fischer and Rainer Schmiedel and Karl-Ludwig Schulte and Balzer, {J{\"o}rn O} and Arne Kieback and Eduard Fiehn and G{\"u}nther Wittenberg and Tammam Ali and Christiane Tiefenbacher and Thomas Jahnke and Steinkamp, {Hermann J} and Karl Wegscheider and Andr{\'a}s Treszl and Maja Ingwersen and Thomas Zeller",
year = "2014",
month = aug,
day = "1",
doi = "10.1583/13-4625R.1",
language = "English",
volume = "21",
pages = "463--471",
journal = "J ENDOVASC THER",
issn = "1526-6028",
publisher = "International Society of Endovascular Specialists",
number = "4",

}

RIS

TY - JOUR

T1 - German multicenter real-world registry of stenting for superficial femoral artery disease: clinical results and predictive factors for revascularization

AU - Krankenberg, Hans

AU - Tübler, Thilo

AU - Sixt, Sebastian

AU - Fischer, Matthias

AU - Schmiedel, Rainer

AU - Schulte, Karl-Ludwig

AU - Balzer, Jörn O

AU - Kieback, Arne

AU - Fiehn, Eduard

AU - Wittenberg, Günther

AU - Ali, Tammam

AU - Tiefenbacher, Christiane

AU - Jahnke, Thomas

AU - Steinkamp, Hermann J

AU - Wegscheider, Karl

AU - Treszl, András

AU - Ingwersen, Maja

AU - Zeller, Thomas

PY - 2014/8/1

Y1 - 2014/8/1

N2 - PURPOSE: To investigate nitinol stent treatment of superficial femoral artery (SFA) lesions and the impact of different risk factors on the need for clinically driven target lesion revascularization (TLR) in a large, real-world population of claudicants.METHODS: Patients presenting with symptomatic SFA stenosis >70% were consecutively enrolled in the 13-center MARIS prospective registry (ClinicalTrials.gov identifier NCT01067885). There was no restriction on lesion length, thus leading to the inclusion of a real-world as well as high-risk patient cohort. The 998 participating patients (657 men; mean age 67.4±9.2 years) had 1050 lesions treated with the same nitinol stent type. The mean lesion length was 9.5±9.6 cm (range 0.5-44; median 8.0); more than a third of the lesions (450, 42.9%) were total occlusions. The primary endpoint was the need for clinically driven target lesion revascularization (TLR) at 12 months.RESULTS: Acute technical success was achieved in 1042 (99.2%) lesions. Restenosis occurred in 187 (23.7%) and reocclusion in 79 (10.0%) lesions at 12 months. The primary endpoint of TLR at 12 months was reached by 136 (17.2%) patients. The periprocedural complication rate was 5.4%. Independent predictors of TLR were female gender [odds ratio (OR) 0.5, 95% confidence interval (CI) 0.3 to 0.7, p<0.001] and lesion length >20 cm vs. 10 cm (OR 2.7, 95% CI 1.1 to 6.6, p=0.029) and 10-20 cm vs. 10 cm (OR 1.9, 95% CI 1.0 to 4.1, p=0.047).CONCLUSION: Stent implantation in the SFA is safe and associated with favorable acute and midterm results in a real-world setting. Lesion length and female gender were identified as independent risk factors for TLR.

AB - PURPOSE: To investigate nitinol stent treatment of superficial femoral artery (SFA) lesions and the impact of different risk factors on the need for clinically driven target lesion revascularization (TLR) in a large, real-world population of claudicants.METHODS: Patients presenting with symptomatic SFA stenosis >70% were consecutively enrolled in the 13-center MARIS prospective registry (ClinicalTrials.gov identifier NCT01067885). There was no restriction on lesion length, thus leading to the inclusion of a real-world as well as high-risk patient cohort. The 998 participating patients (657 men; mean age 67.4±9.2 years) had 1050 lesions treated with the same nitinol stent type. The mean lesion length was 9.5±9.6 cm (range 0.5-44; median 8.0); more than a third of the lesions (450, 42.9%) were total occlusions. The primary endpoint was the need for clinically driven target lesion revascularization (TLR) at 12 months.RESULTS: Acute technical success was achieved in 1042 (99.2%) lesions. Restenosis occurred in 187 (23.7%) and reocclusion in 79 (10.0%) lesions at 12 months. The primary endpoint of TLR at 12 months was reached by 136 (17.2%) patients. The periprocedural complication rate was 5.4%. Independent predictors of TLR were female gender [odds ratio (OR) 0.5, 95% confidence interval (CI) 0.3 to 0.7, p<0.001] and lesion length >20 cm vs. 10 cm (OR 2.7, 95% CI 1.1 to 6.6, p=0.029) and 10-20 cm vs. 10 cm (OR 1.9, 95% CI 1.0 to 4.1, p=0.047).CONCLUSION: Stent implantation in the SFA is safe and associated with favorable acute and midterm results in a real-world setting. Lesion length and female gender were identified as independent risk factors for TLR.

U2 - 10.1583/13-4625R.1

DO - 10.1583/13-4625R.1

M3 - SCORING: Journal article

C2 - 25101571

VL - 21

SP - 463

EP - 471

JO - J ENDOVASC THER

JF - J ENDOVASC THER

SN - 1526-6028

IS - 4

ER -